|
Ontology
|
ID
|
Description
|
GeneRatio
|
BgRatio
|
p value
|
FDR
|
q value
|
| KEGG |
hsa05418 |
Fluid shear stress and atherosclerosis |
24/150 |
139/8076 |
3.87E-17 |
9.95E-15 |
4.57E-15 |
| KEGG |
hsa05205 |
Proteoglycans in cancer |
25/150 |
205/8076 |
3.74E-14 |
4.81E-12 |
2.21E-12 |
| KEGG |
hsa05215 |
Prostate cancer |
18/150 |
97/8076 |
1.19E-13 |
9.19E-12 |
4.22E-12 |
| KEGG |
hsa01522 |
Endocrine resistance |
18/150 |
98/8076 |
1.43E-13 |
9.19E-12 |
4.22E-12 |
| KEGG |
hsa01521 |
EGFR tyrosine kinase inhibitor resistance |
16/150 |
79/8076 |
7.08E-13 |
2.60E-11 |
1.19E-11 |
| KEGG |
hsa04933 |
AGE-RAGE signaling pathway in diabetic complications |
17/150 |
100/8076 |
2.66E-12 |
7.59E-11 |
3.48E-11 |
| KEGG |
hsa04625 |
C-type lectin receptor signaling pathway |
17/150 |
104/8076 |
5.15E-12 |
1.32E-10 |
6.08E-11 |
| KEGG |
hsa05161 |
Hepatitis B |
20/150 |
162/8076 |
1.33E-11 |
2.86E-10 |
1.31E-10 |
| KEGG |
hsa04917 |
Prolactin signaling pathway |
14/150 |
70/8076 |
2.50E-11 |
4.94E-10 |
2.26E-10 |
| KEGG |
hsa04014 |
Ras signaling pathway |
23/150 |
232/8076 |
3.42E-11 |
6.29E-10 |
2.88E-10 |
| KEGG |
hsa04931 |
Insulin resistance |
16/150 |
108/8076 |
1.06E-10 |
1.60E-09 |
7.32E-10 |
| KEGG |
hsa05163 |
Human cytomegalovirus infection |
22/150 |
225/8076 |
1.26E-10 |
1.70E-09 |
7.82E-10 |
| KEGG |
hsa04010 |
MAPK signaling pathway |
25/150 |
294/8076 |
1.26E-10 |
1.70E-09 |
7.82E-10 |
| KEGG |
hsa05145 |
Toxoplasmosis |
16/150 |
112/8076 |
1.85E-10 |
2.38E-09 |
1.09E-09 |
| KEGG |
hsa04151 |
PI3K-Akt signaling pathway |
27/150 |
354/8076 |
2.50E-10 |
3.06E-09 |
1.41E-09 |
| KEGG |
hsa05167 |
Kaposi sarcoma-associated herpesvirus infection |
20/150 |
193/8076 |
3.33E-10 |
3.90E-09 |
1.79E-09 |
| KEGG |
hsa04066 |
HIF-1 signaling pathway |
15/150 |
109/8076 |
1.21E-09 |
1.20E-08 |
5.50E-09 |
| KEGG |
hsa04722 |
Neurotrophin signaling pathway |
15/150 |
119/8076 |
4.22E-09 |
3.61E-08 |
1.66E-08 |
| KEGG |
hsa05162 |
Measles |
16/150 |
139/8076 |
4.80E-09 |
3.85E-08 |
1.77E-08 |
| KEGG |
hsa05210 |
Colorectal cancer |
13/150 |
86/8076 |
5.04E-09 |
3.93E-08 |
1.80E-08 |
| KEGG |
hsa05235 |
PD-L1 expression and PD-1 checkpoint pathway in cancer |
13/150 |
89/8076 |
7.76E-09 |
5.87E-08 |
2.69E-08 |
| KEGG |
hsa05212 |
Pancreatic cancer |
12/150 |
76/8076 |
1.21E-08 |
8.89E-08 |
4.08E-08 |
| KEGG |
hsa04210 |
Apoptosis |
15/150 |
136/8076 |
2.69E-08 |
1.87E-07 |
8.56E-08 |
| KEGG |
hsa04015 |
Rap1 signaling pathway |
18/150 |
210/8076 |
5.52E-08 |
3.38E-07 |
1.55E-07 |
| KEGG |
hsa05218 |
Melanoma |
11/150 |
72/8076 |
7.18E-08 |
4.19E-07 |
1.92E-07 |
| KEGG |
hsa05223 |
Non-small cell lung cancer |
11/150 |
72/8076 |
7.18E-08 |
4.19E-07 |
1.92E-07 |
| KEGG |
hsa04510 |
Focal adhesion |
17/150 |
201/8076 |
1.61E-07 |
8.47E-07 |
3.88E-07 |
| KEGG |
hsa04071 |
Sphingolipid signaling pathway |
13/150 |
119/8076 |
2.67E-07 |
1.32E-06 |
6.06E-07 |
| KEGG |
hsa04012 |
ErbB signaling pathway |
10/150 |
85/8076 |
3.44E-06 |
1.42E-05 |
6.53E-06 |
| KEGG |
hsa05221 |
Acute myeloid leukemia |
9/150 |
67/8076 |
3.53E-06 |
1.42E-05 |
6.53E-06 |
| KEGG |
hsa04664 |
Fc epsilon RI signaling pathway |
9/150 |
68/8076 |
4.01E-06 |
1.56E-05 |
7.16E-06 |
| KEGG |
hsa05214 |
Glioma |
9/150 |
75/8076 |
9.14E-06 |
3.41E-05 |
1.56E-05 |
| KEGG |
hsa04370 |
VEGF signaling pathway |
8/150 |
59/8076 |
1.17E-05 |
4.23E-05 |
1.94E-05 |
| KEGG |
hsa04072 |
Phospholipase D signaling pathway |
11/150 |
148/8076 |
9.06E-05 |
2.88E-04 |
1.32E-04 |
| KEGG |
hsa05211 |
Renal cell carcinoma |
7/150 |
69/8076 |
2.73E-04 |
7.88E-04 |
3.61E-04 |
| KEGG |
hsa05230 |
Central carbon metabolism in cancer |
7/150 |
70/8076 |
2.98E-04 |
8.50E-04 |
3.90E-04 |
| KEGG |
hsa05206 |
MicroRNAs in cancer |
14/150 |
310/8076 |
0.002 |
0.004 |
0.002 |
| KEGG |
hsa04630 |
JAK-STAT signaling pathway |
9/150 |
162/8076 |
0.003 |
0.007 |
0.003 |
| KEGG |
hsa04919 |
Thyroid hormone signaling pathway |
7/150 |
121/8076 |
0.007 |
0.015 |
0.007 |
